Results 21 to 30 of about 4,260 (165)

EPIPOX: Immunoinformatic Characterization of the Shared T-Cell Epitome between Variola Virus and Related Pathogenic Orthopoxviruses [PDF]

open access: yes, 2015
Concerns that variola viruses might be used as bioweapons have renewed the interest in developing new and safer smallpox vaccines. Variola virus genomes are now widely available, allowing computational characterization of the entire T-cell epitome and ...
Molero Abraham, Magdalena   +4 more
core   +2 more sources

Monkeypox and the eye [PDF]

open access: yes, 2023
KEYWORDS monkey pox, Orthopoxviruses, transmission, communicable disease, conjunctivitides, blepharitides, scleritides, keratitides, uveitides, acquired blindness, pandemic, COVID ...
Sibeveih, Zahra
core   +2 more sources

TRIM5α restricts poxviruses and is antagonized by CypA and viral protein C6 [PDF]

open access: yes, 2023
Human tripartite motif protein 5a (TRIM5α) is a well-characterised restriction factor for some RNA viruses including HIV, but against DNA viruses reports are limited.
Lu, Y   +5 more
core   +8 more sources

Table_1_Capripoxviruses, leporipoxviruses, and orthopoxviruses: Occurrences of recombination.docx

open access: yes, 2022
Poxviruses are double-stranded DNA viruses with several members displaying restricted host ranges. They are genetically stable with low nucleotide mutation rates compared to other viruses, due to the poxviral high-fidelity DNA polymerase. Despite the low
Ali Mazloum (13915170)   +3 more
core   +1 more source

Studies of Anti-Viral Activity of Chemically Synthesized Compounds against Orthopoxviruses in vitro

open access: yesПроблемы особо опасных инфекций, 2013
for ST-246 and NIOC-14 is within the range of 0,001-0,004 µg/ml, and IS for both of them is > 100000. In addition, ST-246 and NIOC-14 chemical compound efficacy, concentrated up to 0,0125; 0,025 and 0,05 µg/ml, in accordance with prophylactic charts ...
A. S. Kabanov   +12 more
doaj   +1 more source

Assessing immunogenicity and protectiveness of the vaccinia virus LIVP-GFP in three laboratory animal models

open access: yesИнфекция и иммунитет, 2022
Smallpox eradication and lack of adequate animal model for smallpox infection underlies a necessity to assess immunogenic and protective properties of genetic engineering-created live attenuated smallpox vaccines in several animal models of orthopoxviral
S. N. Shchelkunov   +4 more
doaj   +1 more source

TRIM5α restricts poxviruses and is antagonized by CypA and the viral protein C6. [PDF]

open access: yes, 2023
Human tripartite motif protein 5α (TRIM5α) is a well-characterized restriction factor for some RNA viruses, including HIV1-5; however, reports are limited for DNA viruses6,7.

core   +2 more sources

Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain

open access: yesБиопрепараты: Профилактика, диагностика, лечение, 2023
In 1980, the World Health Assembly officially declared smallpox eradicated in the world, which allowed developed countries to stop preventive vaccination against this disease.
L. F. Stovba   +4 more
doaj   +1 more source

IC50 infectivity values for tested Orthopoxviruses.

open access: yes, 2015
IC50 infectivity values for tested Orthopoxviruses.
Victoria Olson (210647)   +5 more
core   +1 more source

Bayesian reconstruction of the evolutionary history and cross-species transition of variola virus and orthopoxviruses [PDF]

open access: yes, 2018
Variola virus (VARV), the causative agent of smallpox, is an exclusively human virus belonging to the genus Orthopoxvirus, which includes many other viral species covering a wide range of mammal hosts, such as vaccinia, cowpox, camelpox, taterapox ...
Bergna, Annalisa   +11 more
core   +1 more source

Home - About - Disclaimer - Privacy